The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...
Please provide your email address to receive an email when new articles are posted on . Two different doses of CC-90001 vs. placebo slowed decline of percentage of predicted FVC at week 24.
Please provide your email address to receive an email when new articles are posted on . Adverse events reported with ENV-101 have been seen with other hedgehog inhibitors. Another trial is already ...
There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), ...
WARRINGTON, Pa., Jan. 19, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCOD) has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent ...
SAN FRANCISCO--(BUSINESS WIRE)--Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results